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Abstract
Background: During epithelial-to-mesenchymal transition, cancer cells lose adhe-
sion capacity gaining migratory properties. The role of the process on prognosis has
been evaluated in 50 cases of laryngeal carcinoma.
Methods: E-cadherin, N-cadherin, b-catenin, a-catenin, g-catenin, caveolin-1, and
vimentin immunohistochemical expression were evaluated using a double score
based on staining intensity and cellular localization.
Results: Cytoplasmic E-cadherin and a/g catenin staining were associated with a
decrease in survival, cytoplasmic b-catenin was associated with advanced stage, and
N-cadherin and vimentin expression were associated with poor differentiation and
tumor relapse. On the basis of cancer cells, epithelial or mesenchymal morphological
and immunophenotypic similarity we identified 4 main subgroups correlated with a
transition to a more undifferentiated phenotype, which have a different pattern of
relapse and survival.
Conclusion: The negative prognostic role of epithelial-to-mesenchymal transition
has been confirmed and a predictive role in glottic tumors has been suggested, leading
us to propose epithelial-to-mesenchymal transition as an additional adverse feature in
laryngeal carcinoma.
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1 | INTRODUCTION
Laryngeal squamous cell carcinoma (SCC) is a relatively rare
cancer burdened by a high morbidity and mortality rate,1
strongly correlated with tobacco smoking and alcohol intake.2
Disease stage is the main validated prognostic factor3,4 because
a molecular classification is still not available in laryngeal
SCC. Moreover, the site of the laryngeal tumor significantly
affects prognosis5 as well as the pathologic features of the
tumor6 and the Ki-67 labeling index.7 However, innovative
biomarkers that are able to define the biological behavior of
the tumor are urgently needed in order to assess the risk of
recurrence and tailor the patient’s therapy, but they need to be
validated and translated into clinical practice.8,9 It was estab-
lished by several studies that epithelial-to-mesenchymal transi-
tion (ie, the rapid and often reversible changing from the
epithelial morphology to a mesenchymal phenotype) is linked
to unfavorable prognostic markers and poor prognosis in sev-
eral cancers, including laryngeal SCC.10,11 During epithelial-
to-mesenchymal transition, cancer cells lose their mechanisms
of adhesion and acquire the anchorage-independent growth
ones, which lead to migration, invasion, increased metastatic
potential, immunosuppression,12 and drug resistance.13 The
critical step during epithelial-to-mesenchymal transition is the
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“cadherin switch,”14 which is the decrease in the expression of
E-cadherin, a transmembrane receptor, essential in the forma-
tion of intercellular junctions,15 associated to a simultaneous
increase of the expression of the transmembrane cell-cell adhe-
sion protein N-cadherin. The “cadherin switch” provides a
mechanism for transendothelial migration, anoikis resistance,
and increased invasiveness.16 Others proteins involved in the
epithelial-to-mesenchymal transition are the a, b, and g cate-
nins, which colocalizes with E-cadherin at the cytoplasmic
domain, connecting by linking the b-catenin/cadherin complex
to the intracellular cytoskeleton actin fibers, as well as the mes-
enchymal marker vimentin, a cytoskeletal intermediate fila-
ment type III.17 b-catenin in the cytoplasm, freed from its
assembling with E-cadherin,18 is also involved in the canonical
Wnt signaling pathway, taking part in modulation of cell pro-
liferation and signal transduction.19,20 Several studies have
reported its translocation into the nucleus, where b-catenin
acts as a cofactor for the transcription T-cell factor leading to
epithelial-to-mesenchymal transition21 and poor prognosis.22
Finally, the scaffolding protein caveolin-1 is involved in the
growth factor-induced process of disassembling of adheren
junctions and desmosomes.23–25
The purpose of this study was to highlight a possible
association between mesenchymal phenotype acquisition and
adverse clinicopathological prognostic factors as well as the
recurrence rate, the patient’s disease-free survival (DFS), and
overall survival (OS) by evaluating the expression of a panel
of different epithelial-to-mesenchymal transition markers in
50 patients affected by laryngeal SCC. The possibility that
epithelial-to-mesenchymal transition could identify, in the con-
text of tumors with the same pathological stage, a subset of can-
cers that have different prognosis has also been investigated. In
this report, we confirm that epithelial-to-mesenchymal transition
is a critical process strongly correlated with an aggressive clini-
cal behavior in laryngeal SCC.
2 | MATERIALS AND METHODS
2.1 | Clinical data and tissue samples
Formalin-fixed paraffin-embedded tissue of laryngeal SCC
retrieved from the archived specimens of the Division of
Pathology, Sapienza University of Rome, were obtained from
46 patients undergoing surgery with radical intent for laryngeal
SCC from March 2006 to October 2013. In addition, 4 early-
stage laryngeal SCC tumors treated without lymph node dis-
section (Nx) on the basis of a negative baseline imaging for
lymph node involvement (cN0) were included. The study has
been submitted and approved by the Bioethics Committee of
Policlinico Umberto I, Rome, and was compliant with the
reporting recommendations for tumor marker prognostic study
(REMARK) recommendations.26 The patients, informed dur-
ing the follow-up, gave their consent for the study. Primary
surgical treatment and any standard adjuvant strategies27 are
listed in Table 1. All patients underwent follow-up as
advised.27 The main exclusion criteria of the study were a pre-
vious multimodal treatment intended to preserve the larynx, as
well as the presence of multifocal or multicentric cancers, posi-
tive margins, metastatic disease, and nonadherence to the
follow-up program. For each laryngeal carcinoma, all the
hematoxylin-eosin–stained tissue slides obtained from a suita-
ble sampling of surgical specimen, used for histological diag-
nosis (evaluation of microscopic features, and grading and
staging of the neoplasia), were reexamined and the more repre-
sentative slides (1 or 2 sections) were selected for the immuno-
histochemical study. Sections of normal epithelium adjacent
the carcinomas of each patient was used as the control. On the
basis of the risk of relapse, we classified the patients as: (i)
low risk (stages I and II); (ii) intermediate risk (T3 with
adverse pathologic primary site features and/or N1), further
divided in low grade (G1/G2) or high grade (G3/G4); and (iii)
poor risk (T4 and/or N2). The DFS and OS were recorded as
well as the site of relapse (regional or systemic). The occur-
rence of second primary tumors was also remarked.
2.2 | Immunohistochemistry
From selected paraffin tissue blocks, consecutive tissue sec-
tions (2 microns) of tumor and normal samples were cut and
used for the immunohistochemical (IHC) study. The sections
were deparaffinized and rehydrated and used for IHC study.
Endogenous peroxidase activity was blocked with 3% hydro-
gen peroxide and antigen retrieval was made by boiling them
in citrate buffer (0.01 mol/L, pH6) with microwaves (750
W). Then the sections were incubated for 1 hour at room
temperature (RT) with primary antibodies: anti-caveolin-1
TABLE 1 Surgical primary treatment and adjuvant strategies
No. of cases %
Surgery 50
Partial laryngectomy 24 48
Total laryngectomy 26 52
Neck dissection 46 92
Adjuvant radiotherapya 4 8
Adjuvant radiochemotherapyb 24 48
aRadiotherapy was administered in pT3-negative lymph node or pT3-positive
single lymph node cancers with at least one adverse features (perineural, lym-
phatic, or vascular invasion).
bAdjuvant radiochemotherapy was administered in pN2 or pN3 nodal disease,
extracapsular nodal spread, adverse pathologic primary site features (pT4
primary, perineural, lymphatic, or vascular invasion). Cisplatin (100mg/m2
every 21 days i.v.) was the concurrent systemic therapy administered.
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(clone N-20, sc-894, 1:50), anti-E-cadherin (clone H-108, sc-
7870, 1:100), anti-a-catenin (clone H-297, sc-7894, 1:50),
anti-b-catenin (clone H-102, sc-7199, 1:50), anti-g-catenin
(clone H-80, sc-7900, 1:100), and anti-N-cadherin (clone H-
63, sc-7939, USA, 1:50), were all obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). Anti-vimentin (clone V9,
M0725, 1:100) and anti-Ki67 (clone M7240, 1:50) were
obtained from Dako, Glostrup, Denmark. Universal LSAB2
System-HRP (Dako) was used to label the primary antibody.
The reaction product was visualized with 3,3-diaminobenzi-
dine (Dako). The sections were counterstained with Mayer’s
hematoxylin. Negative control was obtained by omitting the
primary antibody. The immunostainings were evaluated
using a semiquantitative double score based on staining
intensity (05 negative, 15weak, 25moderate, and
35 strong) and localization (I5membrane, II5membrane
and cytoplasmic, III5 cytoplasmic, IV5membrane, cyto-
plasmic, and nuclear, V5 cytoplasmic and nuclear, and
VI5 nuclear).28 Tumors with a value !15 positive cells for
Ki67 immunostaining were classified as high kinetic index.
The IHC evaluation was performed by 2 experienced investi-
gators (C.R.d.G. and C.R.), not informed about the antibody
used. Each investigator analyzed all the tumor areas in the
slides (magnification3 1.5,3 4, and3 20) for each antibody
staining for 3 times and the scoring of the staining was calcu-
lated as weighed mean (interobserver agreement 0.81).
Laryngeal SCCs were classified in accordance to morpholog-
ical and immunophenotypic characteristics as: (i) epithelial-
like, when similar to the normal epithelium; (ii) in transition,
when tumor cells are losing epithelial characteristics but
have not yet acquired a mesenchymal phenotype; and (iii)
mesenchymal-like, when the tumor cells have lost their
epithelial phenotype and acquire mesenchymal features.
2.3 | Statistical analysis
Statistical analysis was performed using SPSS software
(SPSS, Chicago, IL). Association between parameters was
TABLE 2 Characteristics of the patients, histological features, and
survival parameters
Characteristics No. of cases
Race
White 50
Sex ratio M:/F 5:1
Female 8
Male 42
Mean age, year (range) 64.66 10
(range 47-87)
<65 23
>65 27
Smoking status
Never smoker 2
Ex-smokera 12
Former smokerb 21
Still smokerc 15
Alcohol
Alcohol user 33
No alcohol 17
Tumor localization
Glottic 37
Supraglottic 13
Microscopic type tumors
Keratinizing SCC 3
Nonkeratinizing SCC 42
Sarcomatoid carcinoma (Spindle-cell carcinoma) 5
T and N classification distribution
T1-T2 20
T3-T4 30
N0 22
N1-N2 24
Risk classes
Low risk 10
Intermediate risk 13
Poor risk 27
Tumor grading
G1-G2 24
G3-G4 26
Proliferation index
Ki67< 15 25
Ki67! 15 25
Relapse
Relapsed 27
No Relapse 23
(Continues)
TABLE 2 (Continued)
Characteristics No. of cases
DFS
5-y 24
OS
5-y 24
Abbreviations: DFS, disease-free survival; OS, overall survival; SCC, squamous
cell carcinoma.
aPatients who had discontinued tobacco use at least 5 years before the diagnosis
of laryngeal SCC.
bpatients who continued to smoke up to laryngeal SCC diagnosis.
cpatients who continued to smoke after laryngeal SCC diagnosis.
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evaluated by the chi-square (and Fisher’s exact) 2-sided test.
DFS was calculated from diagnosis to disease progression,
and OS was calculated from diagnosis to the date of death
with the Kaplan-Meier method. Finally, a log-rank test was
performed to evaluate the statistical significance of difference
in survival. A P value< .05 was considered statistically sig-
nificant. The probability that a mesenchymal-like patient
developed a relapse (the positive predictive value of
mesenchymal-like patients), was calculated by the ratio
between the number of mesenchymal-like patients who devel-
oped a relapse and the total of mesenchymal-like patients.
3 | RESULTS
The characteristics of patients and the histological features of
the tumor, including TNM staging sec Union for Interna-
tional Cancer Control 200929 and World Health Organization
grading, as well as tumor localization and survival parame-
ters are listed in Table 2. The median follow-up of patients
was 35 months. The overall relapse rate was 54% (27/50)
with a local relapse rate of 33% (9/27). The predominant
sites of metastasis were the lungs (13/18; 72%) and mediasti-
nal lymph nodes (5/18; 28%), which was associated in 4
cases with locoregional recurrence. The 3-year and 5-year
DFS were 25 of 505 50% and 24 of 505 48%, respectively,
whereas the 3-year and 5-year OS were 28 of 505 56% and
24 of 505 48%, with a cancer-specific survival of 25 of
505 50%. Survival has also been affected in 3 patients by
the onset of a second metachronous primary tumor. The DFS
(P< .002), OS (P< .001) and the relapse rate (P< .019)
were significantly different in the 3 classes of risk (Support-
ing Information Figure S1). Moreover, disease relapse nega-
tively affected 5-year OS (P< .001; Table 3).
Immunohistochemical expression and
correlation with outcome
Mesenchymal-like behavior of caveolin-1
In our study, all laryngeal SCCs examined did not exhibit
the normal laryngeal mucosa expression pattern of caveolin-
1 (1-I). In fact, 9 of 50 cases (18%) of laryngeal SCC
revealed a strong membrane and cytoplasmic staining (3-II)
corresponding to the initial step of caveolin-1 deregulation.
The 41 of 50 cases (82%) presented a strong and exclusive
cytoplasmic staining (3-III), which matches a further step of
caveolin-1 deregulation (Supporting Information Figure S2 -
1a,b,c). The ubiquitary alteration of caveolin-1 highlighted in
laryngeal SCC did not allow us to detect any significant dif-
ference between the protein expression or its translocation
and any of the prognostic factors considered in conjunction
with survival parameters (Table 4).
E-cadherin quantitative and qualitative
alteration in laryngeal squamous cell
carcinoma
In the control samples, the expression pattern of the E-
cadherin was strong, homogeneous, and mainly limited to
the cell membrane (3-I) as expected. An intense E-cadherin
staining on cell membrane (3-I) has only been evidenced in
3 tumors, whereas 23 cancers (46%) showed the simultaneous
localization of E-cadherin on the membrane and in the cyto-
plasm (3-II). An abnormal and exclusive cytoplasmic staining
(3-III) was highlighted in 48% of tumor samples (Supporting
Information Figure S2 - 2a,b,c). We report that DFS and the
OS were significantly different in the 3 different patterns of
E-cadherin expression with a significant decreased OS and
DFS in tumors with an abnormal cytoplasmic E-cadherin
accumulation (respectively, P< .068 and P< .010; Table 4).
Intracytoplasmic a, b, and c catenin storage
The normal mainly limited cell membrane expression pattern
of b-catenin was rare (6/50; 12%) in the tumor samples ana-
lyzed (3-I). An abnormal cytoplasmic localization associated
with membrane staining (3-II; 68%) or even exclusively
cytoplasmic (3-III; 20%) was highlighted in the majority of
laryngeal SCCs. The relocation of the b-catenin was consist-
ent with the late stages in the developmental process of
epithelial-to-mesenchymal transition (Supporting Information
Figure S2 - 3a,b,c). We report a significant association
between the abnormal storage of b-catenin in cancer cell
cytoplasm and the T3-T4 group (P< .017; Table 4). The
DFS and OS were different in the 3 patterns of expression of
b-catenin, but the worst survival curve was observed in
tumors with initial b-catenin deregulation (P< .001 and
P< .002) compared with tumors with abnormal advanced
b-catenin cytoplasmic accumulation. In addition, the abnormal
TABLE 3 Patient risk, laryngeal subsite, disease-free survival, and
overall survival in relation to the disease relapse
Variables No. of cases Relapse No Relapse P value
Low risk 10 2 (20%) 8 (80%) .0194
Intermediate risk 13 6 (46%) 7 (54%)
Poor risk 27 19 (70%) 8 (30%)
Glottic 37 17 (46%) 20 (54%)
Supraglottic 13 10 (77%) 3 (23%)
5-y DFS 24 1 (4%) 23 (96%)
5-y OS 24 5 (21%) 19 (79%) < .001
Abbreviations: DFS, disease-free survival; OS, overall survival.
p-value in bold indicates statistical significance.
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TABLE 4 Antibody cellular localization versus T and N classifications, grade, laryngeal subsite relapse, disease-free survival, and overall
survival
No. of cases Normal pattern Initial deregulation Late deregulation P value
Caveolin-1
T1-T2 20 0 3 (15%) 17 (85%)
T3-T4 30 0 6 (20%) 24 (80%)
G1-G2 24 0 4 (17%) 20 (83%)
G3-G4 26 0 5 (19%) 21 (81%)
N0 22 0 4 (18%) 18 (82%)
N1-N2 24 0 4 (17%) 20 (83%)
Glottic 37 0 8 (22%) 29 (78%)
Supraglottic 13 0 1 (8%) 12 (92%)
Relapse 27 0 4 (15%) 23 (85%)
No relapse 23 0 5 (22%) 18 (78%)
5-y DFS 24 0 6 18
5-y OS 24 0 4 20
E-cadherin
T1-T2 20 1 (5%) 10 (50%) 9 (45%)
T3-T4 30 2 (7%) 13 (43%) 15 (50%)
G1-G2 24 1 (4%) 14 (58%) 9 (38%)
G3-G4 26 2 (8%) 9 (34%) 15 (58%)
N0 22 2 (9%) 10 (45%) 10 (45%)
N1-N2 24 1 (4%) 10 (42%) 13 (54%)
Glottic 37 2 (5%) 18 (49%) 17 (46%)
Supraglottic 13 1 (8%) 5 (38%) 7 (54%)
Relapse 27 2 11 14
No relapse 23 1 12 10
5-y DFS 24 1 13 10 < .010
5-y OS 24 1 11 12 < .006
b-Catenin
T1-T2 20 4 (20%) 15 (75%) 1 (5%) < .017
T3-T4 30 2 (7%) 19 (63%) 9 (30%)
G1-G2 24 3 (12.5%) 18 (75%) 3 (12.5%)
G3-G4 26 3 (12%) 16 (61%) 7 (27%)
N0 22 3 (14%) 15 (68%) 4 (18%)
N1-N2 24 3 (12.5%) 15 (62.5) 6 (25%)
Glottic 37 5 (13%) 24 (65%) 8 (22%)
Supraglottic 13 1 (8%) 10 (77%) 2 (15%)
Relapse 27 3 18 6
No relapse 23 3 16 4
5-y DFS 24 3 17 4 < .001
5-y OS 24 3 17 4 < .002
a-Catenin
T1-T2 20 2 (10%) 3 (15%) 15 (75%)
T3-T4 30 1 (3%) 11 (37%) 18 (60%)
G1-G2 24 1 (4%) 7 (29%) 16 (67%)
G3-G4 26 2 (8%) 7 (27%) 17 (65%)
N0 22 1 (4%) 5 (23%) 16 (73%)
N1-N2 24 2 (8%) 7 (29%) 15 (63%)
Glottic 37 2 (5%) 10 (27%) 25 (68%)
Supraglottic 13 1 (8%) 4 (31%) 8 (61%)
(Continues)
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cytoplasmic accumulation of g and a-catenin were predominant
(respectively, 3-III and 1-III; Supporting Information Figure S2
- 4a,b,c, and 5a,b,c). This pattern of expression was associated
with worse DFS (respectively, P< .045 and P< .001) and OS
(respectively, P< .004 and P< .001; Table 4).
The critical b-catenin nuclear translocation
A nuclear and cytoplasmic staining (3-V) could be revealed
in one locally advanced and poorly differentiated tumor
sample. This glottic cancer fell into the high-risk category,
TABLE 4 (Continued)
No. of cases Normal pattern Initial deregulation Late deregulation P value
Relapse 27 1 8 18
No relapse 23 2 6 15
5-y DFS 24 2 7 15 < .001
5-y OS 24 1 8 15 < .001
g-Catenin
T1-T2 20 1 (5%) 10 (50%) 9 (45%)
T3-T4 30 2 (7%) 9 (30%) 19 (63%)
G1-G2 24 1 (4%) 12 (50%) 11 (46%)
G3-G4 26 2 (8%) 7 (27%) 17 (65%)
N0 22 0 9 (41%) 13 (59%)
N1-N2 24 3 (12.5%) 6 (25%) 15 (62.5%)
Glottic 37 2 (5%) 16 (43%) 19 (51%)
Supraglottic 13 1 (8%) 3 (23%) 9 (69%)
Relapse 27 3 8 16
No relapse 23 0 11 12
5-y DFS 24 0 12 12 < .045
5-y OS 24 1 12 11 < .004
N-cadherin
T1-T2 20 17 (85%) 3 (15%)
T3-T4 30 25 (83%) 5 (17%)
G1-G2 24 24 (100%) 0 < .043
G3-G4 26 18 (69%) 8 (31%)
N0 22 20 (91%) 2 (9%)
N1-N2 24 18 (75%) 6 (25%)
Glottic 37 31 (84%) 6 (16%)
Supraglottic 13 11 (85%) 2 (15%)
Relapse 27 19 8 < .005
No relapse 23 23 0
5-y DFS 24 23 1
5-y OS 24 21 3
Vimentin
T1-T2 20 18 (90%) 2 (10%)
T3-T4 30 19 (63%) 11 (37%)
G1-G2 24 22 (92%) 2 (8%) < .092
G3-G4 26 15 (58%) 11 (42%)
N0 22 18 (82%) 4 (18%)
N1-N2 24 15 (62.5%) 9 (37.5%)
Glottic 37 26 (70%) 11 (30%)
Supraglottic 13 11 (85%) 2 (15%)
Relapse 27 15 12 < .013
No relapse 23 22 1
5-y DFS 24 22 2
5-y OS 24 17 9
Abbreviations: DFS, disease-free survival; G, grade; OS, overall survival.
p-value in bold indicates statistical significance.
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and a metastatic lung progression after 15 months of diagno-
sis was recorded (Supporting Information Figure S2 - 3d).
The “Cadherin switch”
Normal laryngeal mucosa did not express N-cadherin (0), an
aberrant expression of the protein on the cell membrane (2-I)
was highlighted in 8 tumor samples (16%; Supporting
Information Figure S2 - 6a,b). Small neoplastic N-cadherin
positive clusters were exclusively demonstrated in undiffer-
entiated/poorly differentiated tumors (P< .043) and in
patients whose disease had relapsed (P5 .005). We did not
find a significant different N-cadherin expression in the 2
laryngeal subsites (Table 4).
Upregulation of vimentin and a mature
mesenchymal phenotype acquisition
Vimentin staining was moderately positive in the cell sub-
membrane cytoplasm (2-I; 15%) and in the cytoplasm (2-III;
85%) of elongated cells with mesenchymal shape in 13
laryngeal SCCs (26%; Supporting Information Figure S2 -
7a,b, Supporting Information Figure S3). The vimentin
expression was statistically associated to the tumor grade
(P< .092) and with tumor relapse (P< .013). Surprisingly,
the detection of vimentin-positive tumors was more common
in glottic (30%) rather than in supraglottic cancers (15%;
Table 4).
Concordance of epithelial-to-mesenchymal
transition markers expression between each
other
We found that all the markers analyzed were concordant
between each other and highly consistent with the informa-
tion provided, allowing us to detect the framework of differ-
ent steps of the epithelial-to-mesenchymal transition
stepwise process. The detection of abnormal caveolin-1
expression as well as the cadherin/catenin complex break-
down and the pathological accumulation of the proteins in
the cytoplasm up to the expression of the mesenchymal
markers, represent sequential stages recognizable in the neo-
plastic samples. The combination of multiple features pro-
vides an advantage over the information provided by every
single marker on the state of development of the epithelial-
to-mesenchymal transition (Supporting Information Figure
S4). Only a minority (4/50; 8%) of laryngeal SCCs retain an
epithelial-like immunophenotype, whereas a mesenchymal-
like phenotype was achieved in 16 of 50 (32%) tumor sam-
ples (3N-cadherin-positive cancers, 8 vimentin-positive can-
cers, and 5N-cadherin and vimentin-positive cancers). Most
of laryngeal SCC tumors showed an immunophenotype in
transition (30/50; 60%) characterized by a broad continuous
spectrum of alterations ranging from tumors that have an ini-
tial loss of their epithelial characteristics (17/30; 34%) up to
cancers characterized by deep premesenchymal alterations
(13/30; 43%).
Association among epithelial-to-mesenchymal
transition status and clinical data,
histopathological features, smoking status,
proliferation index, and patient risk classes
We found an association between epithelial-to-mesenchymal
transition status with the male sex (P< .041), but the differ-
ent weight between the sexes must be taken into account
(Table 5), and with the degree of differentiation characterized
by a significant increase of anaplasia in mesenchymal tumors
(P< .024; Figure 1A). No correlation could be demonstrated
between epithelial-to-mesenchymal transition status and the
clinical data, including the classes of risk (Table 5).
FIGURE 1 Epithelial-to-mesenchymal transition status influence on differentiation A and relapse B
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Influence of epithelial-to-mesenchymal
transition status on relapse and the survival
parameters
Among the 27 patients who relapsed, 15 cancers (55%) had a
mesenchymal-like immunophenotype, 11 (41%) had a transi-
tion phenotype, and only 1 (4%) tumor had an epithelial-like
phenotype. The relapse rate was 92% (15/16) in the
mesenchymal-like tumors, 25% (1/4) in the epithelial-like
tumors, and 40% (11/30) in the tumors in transition. More-
over, the relapse rate was significantly more frequent 54% (7/
13) in tumors closer to the mesenchymal than in tumors that
have an initial loss of their epithelial characteristics (4/17;
23.5%). This different relapse rate in the different patterns of
epithelial-to-mesenchymal transition was statistically signifi-
cant (P< .005; Figure 1B). Moreover, the immunophenotypic
pattern of epithelial-to-mesenchymal transition significantly
influenced DFS and OS. As shown in Figure 2, the 4 main
subgroups identified highlighted 4 different OS and DFS
curves. Comparison of survival curves was considered statis-
tically significant (respectively, P< .047 and P< .019).
The prognostic and predictive role of
epithelial-to-mesenchymal transition in the
different laryngeal subsites
Despite the aggressive biological behavior of tumors in the
supraglottic area, demonstrated by the fact that many cancers
TABLE 5 Epithelial-to-mesenchymal transition versus clinical data
No. of cases Epithelial-like In transition Mesenchymal-like P value
Male 8 0 8 (100%) 0 < .041
Female 42 4 (10%) 22 (52%) 16 (38%)
<65-y of age 23 1 (4%) 15 (65%) 7 (30%)
>65-y of age 27 3 (11%) 15 (56%) 9 (33%)
Smoker 48 4 (83%) 28 (58%) 16 (33%)
Nonsmoker 2 0 2 (100%) 0
Alcohol use 33 1 (3%) 21 (64%) 11 (33%)
No alcohol use 17 3 (18%) 9 (53%) 5 (29%)
Low-risk 10 1 (10%) 8 (80%) 1 (10%)
Intermediate-risk 13 1 (8%) 9 (69%) 3 (23%)
Poor-risk 27 2 (7%) 13 (48%) 12 (44%)
G1-G2 24 3 (12%) 19 (79%) 2 (83%) < .024
G3-G4 26 1 (4%) 11 (42%) 14 (54%)
T1-T2 20 2 (10%) 14 (70%) 4 (20%)
T3-T4 30 2 (7%) 16 (53%) 12 (40%)
N0 22 2 (9%) 15 (68%) 5 (23%)
N1-N2 24 1 (4%) 12 (50%) 11 (46%)
Glottic 37 3 (8%) 21 (57%) 13 (35%)
Supraglottic 13 1 (8%) 9 (69%) 3 (23%)
Ki67< 15 25 4 (16%) 13 (52%) 8 (32%)
Ki67! 15 25 0 17 (68%) 8 (32%)
Relapse 27 1 (4%) 11 (41%) 15 (55%) < .005
No relapse 23 3 (13%) 19 (83%) 1 (4%)
Abbreviation: G, grade.
p-value in bold indicates statistical significance.
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have fallen into the poor-risk group (11/13), we found only 3
supraglottic mesenchymal-like tumors. The tumors were all
in the poor-risk category and all of them have relapsed. In
addition, all the 5 supraglottic mesenchymal-close tumors
have relapsed too. We highlighted that all the 8 supraglottic
mesenchymal/mesenchymal-close cancers were: (i) in men;
(ii) in the poor-risk group; (iii) associated with predomi-
nantly systemic recurrence (lungs 6/8); and (iv) in patients
who died during the follow-up.
The relapse rate in supraglottic transition epithelial-close
tumors was lower than in the mesenchymal tumors (2/4;
50%) regardless of the risk classes. Unexpectedly, the only
supraglottic epithelial-like cancer fell in the poor-risk cate-
gory and the tumor did not relapse (see Figure 3).
We have found that 81% (13/16) of tumors that exhibit a
mesenchymal-like phenotype were localized in the glottic area.
As opposed to supraglottic cancer, in the glottic area, we high-
lighted the mesenchymal acquisition in tumors of all risk
classes, although the incidence of mesenchymal-like tumors in
the poor-risk group prevailed (9/12). We found mesenchymal-
like tumors both in the low-risk group (1 case) and in the
intermediate-risk group (3 cases), as shown in Figure 3. We
reported that 12 of 13 glottic mesenchymal-like tumors were
recurrent, regardless of the risk stratification, including the
FIGURE 2 Epithelial-to-mesenchymal transition status influence on A, overall survival (OS) and B, disease-free survival [Color figure can be
viewed at wileyonlinelibrary.com]
FIGURE 3 The prognostic and predictive role of epithelial-to-mesenchymal transition in the different laryngeal subsites (yellow5 relapse) [Color
figure can be viewed at wileyonlinelibrary.com]
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low-risk mesenchymal glottic cancer. We stress a positive pre-
dictive value of relapse in the mesenchymal phenotype acqui-
sition of 94%. Moreover, glottic mesenchymal-like tumors
seem to have a more indolent behavior compared with supra-
glottic tumors showing an equal locoregional and systemic
recurrence (6/12; 50%) with 4 of 13 patients (31%) currently
alive. In addition, the recurrence rate in glottic tumors classi-
fied in transition (4/21) was higher in mesenchymal-close (2/8;
25%) versus the epithelial-close cancers (2/13; 15%), regard-
less of the risk stratification. Among the 3 glottic tumors that
expressed the epithelial-like phenotype, 1 experienced recur-
rence (1/3; 33%; see Figure 3).
Epithelial-to-mesenchymal transition status in
tumors treated without lymph node dissection
In 3 of 4 cases, the glottis was the primary site of the small
group of early tumors that underwent neck dissection, and all
were in the low-risk group. One tumor was classified as
epithelial-like and 3 tumors as in transition epithelial-close.
None of the patients treated without lymph node dissection
experienced local, nodal, or systemic recurrence. They were
all disease free and alive.
4 | DISCUSSION
Although the best quantification of the epithelial-to-
mesenchymal transition score is the evaluation of the
epithelial-to-mesenchymal transition key markers by poly-
merase chain reaction, Western Blot, or flow cytometry, sci-
entific investigation of epithelial-to-mesenchymal transition
is hampered by the intrinsic complexity of the process as
well as by the transient nature of the transition, which more-
over is reversible, furthermore it is not activated simultane-
ously and is limited to some cluster of cancer cells.30 The
IHC evaluation of the expression of specific markers of
epithelial-to-mesenchymal transition has allowed us to iden-
tify critical intratumoral areas with loss of epithelial markers
and acquisition of the mesenchymal ones, that seem to be
able to radically modify the biological behavior of the tumor.
Our data confirm that the transition process was character-
ized by a considerable variability, reaching different matura-
tion levels in different cancers and within different areas of
the same tumor. Moreover, the evaluation by IHC staining
allowed us to highlight changes in cellular localization of the
proteins that seem to be extremely significant from a biologi-
cal point of view, as well as the morphological finding of
epithelial cells that have acquired the mesenchymal shape. In
the high prevalence of laryngeal SCCs that we analyzed (46/
50), there was an evident and diffuse alteration of epithelial-
to-mesenchymal transition markers when compared to sur-
rounding healthy tissue, all indicating a tendency to a rife
process of epithelial-to-mesenchymal transition,31 probably
due to a tumor microenvironment especially promoting
epithelial-to-mesenchymal transition in laryngeal SCC.
Indeed, the extracellular matrix, through different cytokines32
and growth factors,33 is able to induce the epigenetic silenc-
ing of E-cadherin expression34 as well as hypoxia35 and
tobacco use.36 Our data evidenced an impressive predomi-
nance of patients who smoked and an alarming number of
patients who continued to smoke even after the cancer diag-
nosis, confirming the “total” evidence that chronic inflamma-
tion, hypoxia, and microenvironment modification induced
by smoke, contribute in carcinogenesis and tumor progres-
sion of laryngeal SCC. Therefore, our findings support the
need to implement an education program to remove this bad
habit in Italy. In addition, the ubiquity of the caveolin-1 qual-
itative and quantitative alterations support caveolin-1 as a
milestone in the epithelial-to-mesenchymal transition trigger
by mediating the growth factor-stimulated disassembly of
epithelial cell-cell adhesion complex23 suggesting indirectly
a tumor microenvironment role in epithelial-to-mesenchymal
transition control. Our results confirm that the panel of
markers correlate with pathologic adverse features of the
tumor in agreement with several studies; an aberrant cyto-
plasm accumulation of the b-catenin was predominantly
found in locally advanced tumors,37,38 the cadherin switch
was demonstrated exclusively in poorly differentiated can-
cers,39 and the vimentin expression has been significantly
associated to the tumor grade.40 Our results confirm that the
epithelial-to-mesenchymal transition markers correlate with
clinical outcome; the cadherin switch was demonstrated
exclusively in relapsed patients39 as well as the vimentin
expression.40 E-cadherin, a-catenin, and g-catenin abnormal
cytoplasmic storage were associated with decreased survival
rates and a shorter DFS.41,42 In addition, our data seem to
suggest that the canonical Wnt pathway may be inactivated
in several laryngeal SCCs. Indeed, b-catenin nuclear staining
was highlighted in only 1 glottic tumor, in agreement with
the data from the study by Goulioumis et al,43 allowing us to
suggest that alternative signals to the Wnt/b-catenin pathway
may be able to negatively influence survival in the late stage
of epithelial-to-mesenchymal transition,44 because both the
DFS and OS were more adversely affected in the early stages
of the b-catenin dysregulation with respect to the late ones,
confirming the Galera-Ruiz et al12 assumptions.
We especially point out that the full panel of studied
markers was overall coherent in the information provided,
and that it was more effective in the tumor behavior predic-
tion when compared to the information provided by every
single marker of epithelial-to-mesenchymal transition. Only
4 tumors (8%) in our series retained an immunophenotype
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similar to the normal epithelium. In others (32%), we
described the immunophenotypic completion of epithelial-to-
mesenchymal transition associated with the appearance of
mesenchymal traits. On the contrary, we found in most of
the cases (60%) that some cells were in the phase of the pro-
gressive loss of epithelial markers without having yet
acquired the mesenchymal ones. In this predominant group
of tumors in transition, we identified 2 more subgroups, not
preplanned, on the basis of their closeness to be epithelial or
mesenchymal. The stepwise process of the transitional status
significantly correlated with a transition to a more aggressive
undifferentiated phenotype with poorer prognosis and was
highly predictive of the disease outcome in laryngeal SCC. The
relapse rate within the mesenchymal-like tumors was higher
(92%) in respect to every other prognostic factor considered.
The recurrence rate was high (53%) in mesenchymal-close can-
cers also. The lowest recurrence rate has been found in
epithelial-like phenotype tumors (20%) and in epithelial-close
cancers (23.5%). The different relapse rate among the progres-
sive stage of epithelial-to-mesenchymal transition was statisti-
cally significant. In addition, the OS was significantly different
in the 4 different patterns of epithelial-to-mesenchymal transi-
tion expressions and 4 different survival curves were high-
lighted by the degree of epithelial-to-mesenchymal transition,
overcoming the limited risk prediction based on standard clini-
cal and pathological factors. In effect, only a very small group
of glottic and supraglottic tumors (5; 10%) bearing an epithelial
immunophenotype (like and close) has experienced disease
relapse, probably related to epithelial-to-mesenchymal transition
alternative pathways carriers in tumor progression and meta-
static potential acquisition. A significant biological difference
was stressed in glottic versus supraglottic cancers. Our data
evidenced an aggressive biological behavior of supraglottic can-
cers as reported,11 but we underline that a poor outcome was
present in all patients with supraglottic mesenchymal-like and
mesenchymal-close cancers. However, supraglottic epithelial
tumors showed a lower aggressive profile, confirming the
strongly negative prognostic role of epithelial-to-mesenchymal
transition in supraglottic cancers. Paradoxically, tumors with
mesenchymal-like phenotypes were more frequent among the
usually less aggressive glottic tumors and distributed in all
classes of risk, even in the good-risk class. The acquisition of a
mesenchymal phenotype in glottic cancers significantly corre-
lates with relapse, allowing us to select the relapse candidates.
The high positive predictive value (94%) of the epithelial-to-
mesenchymal transition status allows us to consider epithelial-
to-mesenchymal transition as a negative prognostic factor and
an independent predictor of relapse in glottic cancers.
In addition, we evaluated the small group of early tumors
that did not undergo the neck dissection at the time of sur-
gery. Our series is not appropriate to recommend elective
lymph node dissection versus therapeutic lymphadenectomy
in case of nodal relapse, but we underline how early detec-
tion of small tumors was associated with low clinical risk
and high curability rate and was able to prevent the activa-
tion of the epithelial-to-mesenchymal transition program
with a relevant prognostic impact.
In conclusion, our results highlight that the gradual step-
wise process of epithelial-to-mesenchymal transition is
mainly evident in undifferentiated laryngeal SCC and in
relapsing patients and that it negatively influenced DFS and
OS. The association between epithelial-to-mesenchymal tran-
sition status and adverse prognosis may be important for
changing clinical practices, even considering the small num-
ber of patients and the limitation of data emerging from ret-
rospective collections.
Therefore, we propose to consider the acquisition of mes-
enchymal markers as an additional adverse feature by which
to get adjuvant treatment decisions for patients with laryngeal
SCC.
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